REGN727/SAR236553, A FULLY HUMAN PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) MONOCLONAL ANTIBODY: EFFECTS ON SAFETY AND LIPID AND LIPOPROTEIN PROFILES WHEN ADMINISTERED SUBCUTANEOUSLY  by Swergold, Gary et al.
 BEST POSTERS AWARDS
E2023
JACC April 5, 2011
Volume 57, Issue 14
REGN727/SAR236553, A FULLY HUMAN PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) 
MONOCLONAL ANTIBODY: EFFECTS ON SAFETY AND LIPID AND LIPOPROTEIN PROFILES WHEN 
ADMINISTERED SUBCUTANEOUSLY
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Sunday, April 03, 2011, 10:00 a.m.-4:45 p.m.
Session Title: ACC.11 Best Poster Award Competition
Abstract Category: 14. Pharmacology/Hormones/Lipids—Basic
Session-Poster Board Number:  1182-247
Authors: Gary Swergold, Stephanie Biedermann, Rumiana Renard, Douglas Nadler, Richard Wu, Eleanor A. Lisbon, Maria J. Gutierrez, Scott Mellis, 
Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background: PCSK9 activity is an important determinant of circulating LDL-C levels and is likely a risk factor for developing coronary heart 
disease. PCSK9 gain-of-function mutations may cause autosomal dominant hypercholesterolemia; PCSK9 loss-of-function mutations are 
associated with reduced LDL-C levels and protection from cardiovascular disease. REGN727/SAR236553 (REGN727), a fully human monoclonal 
antibody directed against PCSK9, may have potential as a new therapeutic modality for hypercholesterolemia. Here we report the safety and 
pharmacodynamic effects of REGN727 administered subcutaneously (SC) in a phase 1 clinical trial.
Methods: We randomized healthy men and women ages 18-65 years with LDL-C > 100 mg/dL and fasting triglycerides ≤ 200 mg/dL who were not 
indicated for statin therapy. Thirty-two were randomized to a single SC dose of 1 of 4 escalating doses of REGN727 (n=6 per cohort) or placebo (n=2 
per cohort). Study visits were conducted up to day 106 after administration. Safety measures included treatment-emergent adverse experiences, 
serum chemistry (including liver transaminases, CPK, and troponin I), ECG, and hematology. Pharmacodynamic measures included LDL-C, HDL-C, 
non-HDL-C, ApoB, ApoA1, Lp(a), and triglycerides.
Results: SC administration of all doses of REGN727 was generally safe and well tolerated. There were no clinically meaningful elevations of liver 
transaminases. One subject with previous history of appendectomy experienced an SAE of small bowel obstruction with onset at study day 75; the 
event was considered unrelated to study drug. LDL-C was reduced from baseline in a dose-dependent manner both in degree and duration. In the 
highest dose cohort, mean LDL-C was reduced > 55% from baseline for ≥ 30 days. Reductions in mean total cholesterol (≥ 35% in the higher dose 
cohorts) were commensurate with the effects on LDL-C levels. There was no apparent change in HDL-C from baseline.
Conclusions: SC administration of REGN727 to healthy volunteers with LDL-C > 100 mg/dL resulted in dose-dependent reductions in mean LDL-C. 
No dose-limiting toxicities were observed. REGN727 is being investigated in further studies for the treatment of hypercholesterolemia.
